TrialPsychopharmacology2026

The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial.

Peter C T Hawkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.